Therapy

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial results for the fourth quarter and full-year of 2023 and provided a business update.

Key Points: 
  • “Nana-val is a first-in-class, all-oral combination treatment regimen that has entered late-stage development to target and treat EBV-associated cancers.
  • Completed enrollment of Stage 2 in the R/R EBV+ PTCL cohort of patients treated with Nana-val (n=21, Stage 1 + Stage 2 patients) in the first quarter of 2024.
  • Amended protocol to additionally enable enrollment of second-line R/R EBV+ DLBCL patients and R/R EBV+ PTLD patients, including pediatric EBV+ PTLD patients ≥ 12 years of age.
  • Present Stage 1 + Stage 2 data (n=21) in the R/R EBV+ PTCL cohort in patients treated with Nana-val in the third quarter of 2024.

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

ET

Key Points: 
  • ET
    ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
  • “We expect that 2024 will be an important year for MacroGenics, with multiple pipeline advancements anticipated," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.

Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001

Retrieved on: 
Thursday, March 7, 2024

SAN FRANCISCO, March 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE), will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.

Key Points: 
  • SAN FRANCISCO, March 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE), will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, March 7, 2024

The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement grant consists of a non-qualified stock option to purchase an aggregate of 30,000 shares of the Company's common stock with a 10-year term and an exercise price of $25.75 per share.
  • The option vests as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months.
  • The inducement grant is subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of the Stock Option Agreement.

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Retrieved on: 
Thursday, March 7, 2024

BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings.

Key Points: 
  • BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings.
  • A live webcast and replay of the presentation will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com .

Noom Strengthens Commercial Leadership Team with Trio of Executive Healthcare Appointments

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better and healthier lives, is pleased to announce three key healthcare leadership appointments: Jodi Bryant as President, Healthcare, Matt Moran as Chief Strategy Officer, and Cody Fair as Chief Commercial Officer.

Key Points: 
  • "We are thrilled to welcome Jodi and Matt to the Noom family while also celebrating Cody's well-earned promotion," said Geoff Cook, Chief Executive Officer of Noom.
  • In her new role at Noom, Jodi will lead the Healthcare team, overseeing the company's B2B and Clinical businesses.
  • Prior to joining Noom, Jodi held various leadership positions at renowned organizations such as Mercer, Aetna, and Headspace Health, where she served as Chief Commercial Officer.
  • In his role as Chief Strategy Officer at Noom, Matt will help evolve the strategy and direction of the organization.

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Retrieved on: 
Thursday, March 7, 2024

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell

Key Points: 
  • Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell
    PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.
  • “We are ecstatic about working with the team led by Dr. Pohlmann,” stated Dr. Williams, BriaCell’s President & CEO.
  • “We strongly believe in the therapeutic potential of our novel personalized next-generation vaccine platform and this agreement will be invaluable to us as we advance the clinical development of our off-the-shelf therapies to those cancer patients with persistent unmet medical needs.”
    “Through this agreement, we expect to further our understanding of our novel immunotherapy’s mechanism of action and its use in breast and prostate cancer patients,” stated Dr. Giuseppe Del Priore, BriaCell’s CMO.
  • “Our shared goal is to improve the survival and quality of life in cancer patients who are fighting a disease with a poor prognosis and a short life expectancy.”

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 7, 2024

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.

Key Points: 
  • SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • “Werewolf made considerable progress in 2023, setting up 2024 as a year of execution across our pipeline,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
  • Financial Results for the Fourth Quarter and Full Year 2023:
    Cash position: As of December 31, 2023, cash and cash equivalents were $134.3 million, compared to $129.3 million as of December 31, 2022.
  • Net loss: Net loss was $12.0 million for the fourth quarter of 2023, compared to $11.9 million for the same period in 2022.
  • Net loss was $37.4 million for the full year 2023, compared to $53.8 million for the full year 2022.

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • In October 2023, Neumora announced that Robert Lenz, M.D., Ph.D., had joined Neumora as executive vice president, head of R&D.
  • Cash Position: As of December 31, 2023, Neumora had cash, cash equivalents and marketable securities of $463.8 million.
  • R&D Expense: Research and development expenses for the fourth quarter of 2023 were $38.9 million, as compared to $23.5 million for the same period in 2022.
  • Net Loss: The Company reported a net loss of $108.7 million for the fourth quarter of 2023, as compared to $28.1 million for the same period in 2022.